HSA | FSA CARDS ARE NOW ACCEPTED

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on hormones and fertility. Browse all Hormones & Fertility education

Most conversations about androgen-pathway optimization start with testosterone — how to support it, measure it, monitor it. Far fewer start with the question that matters most for long-term hormonal health: what happens to the biological system that makes testosterone when external support is introduced? The answer lives in the HPTA axis — the hypothalamic-pituitary-testicular signaling loop — and in the genetics governing how sensitively that axis operates, how readily it suppresses under negative feedback, and how reliably it recovers when protocols change. For men who care about fertility alongside hormone optimization, these genetic variables are among the most consequential in the entire panel.

What Is the HPTA Axis and How Does It Work?

The HPTA axis is the hormonal command chain governing endogenous testosterone and sperm production in men. In sequence:

The hypothalamus releases GnRH (gonadotropin-releasing hormone) in pulsatile bursts. GnRH signals the pituitary gland to release LH (luteinizing hormone) and FSH (follicle-stimulating hormone). LH travels to the testes and stimulates Leydig cells to produce testosterone. FSH travels to the testes and stimulates Sertoli cells to support spermatogenesis. Rising testosterone then feeds back to the hypothalamus and pituitary, suppressing GnRH and LH/FSH release — the classic negative feedback loop that keeps the system in equilibrium.

This loop is continuous and self-regulating. When external androgenic signals enter the system, negative feedback suppresses GnRH, LH, and FSH — and the testes, receiving less stimulation, reduce both testosterone production and sperm output. How deeply that suppression occurs, how long it persists, and how completely the axis recovers when protocols are adjusted are all influenced by the genetic variants the PlexusDx Precision Peptide Genetic Test analyzes across 14 pathways, 49 peptides, and 150+ genetic insights.

LH and FSH Receptor Genetics: Where Signaling Becomes Individual

The genetic layer of HPTA function begins at the receptor level. LH and FSH carry their signals from the pituitary, but those signals are only as effective as the receptors that receive them in the testes.

LHCGR (LH/chorionic gonadotropin receptor) — variants in this gene affect the sensitivity of Leydig cells to LH stimulation. Some LHCGR variants are associated with altered receptor expression or binding efficiency, meaning different men require different levels of LH signal to drive equivalent testosterone output from the testes. The same pituitary LH pulse lands differently at the testicular level depending on LHCGR genetics.

FSHR (FSH receptor) — FSH receptor variants similarly affect Sertoli cell responsiveness to FSH signaling. FSHR is among the most extensively studied genetic variables in male reproductive health. Variants associated with reduced receptor sensitivity correlate with lower spermatogenic output at baseline FSH concentrations — directly relevant to fertility preservation conversations.

FSHB (FSH beta subunit) — the FSHB c.-211G>T variant is associated with lower baseline FSH secretion and altered spermatogenic output in some populations. This sits upstream of the receptor, affecting the FSH signal itself before it ever reaches FSHR. A man carrying reduced FSHB bioactivity paired with lower FSHR sensitivity faces a compounded spermatogenic challenge that neither variable alone fully describes.

GNRH1 and GnRH receptor variants — upstream of both LH and FSH, these shape the pulsatile GnRH signal that drives the entire axis, affecting the amplitude and frequency of downstream hormonal output. The pulse pattern of GnRH is essential; continuous rather than pulsatile stimulation desensitizes the pituitary and reduces LH/FSH release.

Why HPTA Genetics Matter for Androgen-Pathway Protocols

When testosterone levels are elevated through any androgen-pathway support strategy, the hypothalamus and pituitary read the elevated androgen signal and reduce GnRH and LH/FSH output via negative feedback. The testes, receiving less LH stimulation, reduce endogenous testosterone production. FSH suppression simultaneously reduces Sertoli cell activity and sperm output. This suppression pattern is well understood — what is less appreciated is how much it varies genetically between men.

Men with different LHCGR, FSHR, and FSHB variants don't suppress at the same rate, to the same depth, or recover at the same pace. LHCGR variants conferring higher baseline receptor sensitivity may respond differently to declining LH under negative feedback than lower-sensitivity variants. FSHR variants already associated with reduced spermatogenic response compound the fertility impact of FSH suppression. Understanding these genetic baselines before a protocol begins gives providers a more complete picture of what they are working with — and what monitoring and preservation strategies the individual's biology actually warrants.

Fertility Preservation and the Genetics of HPTA Recovery

For men of reproductive age on androgen-pathway protocols, or men who want to preserve that option, HPTA genetics are among the most relevant inputs to the provider conversation. Several genetic variables shape the fertility preservation equation directly:

Baseline spermatogenic capacity: FSHR and FSHB variants establish the genetic floor from which any protocol-related suppression works. A man with strong FSH signaling and robust FSHR sensitivity starts from a higher spermatogenic baseline than one whose FSH bioactivity or receptor expression is already at the lower end of the functional range — before any suppression occurs.

LHCGR sensitivity and the GnRH-stimulating pathway: The GnRH-stimulating pathway — which supports LH pulse signaling from the pituitary to the testes — depends on LHCGR receptor responsiveness to translate that LH signal into testicular testosterone production. LHCGR variants shape how effectively this pathway maintains or restores endogenous testosterone production alongside androgen-pathway support, and how the testes respond to renewed LH stimulation when protocols are adjusted.

The fertility-preserving androgen modulation pathway: Selective estrogen receptor modulation at the hypothalamic and pituitary level blocks estrogen's negative feedback signal, allowing endogenous GnRH and LH/FSH to continue pulsing while androgen-pathway support is active. How effectively this approach maintains axis function is partly shaped by ESR1/ESR2 receptor genetics — the same estrogen receptor variants that govern estradiol sensitivity throughout the body. LHCGR and FSHR sensitivity then determine how well the testes respond to the preserved LH and FSH signal.

Axis recovery dynamics: When androgen-pathway support is adjusted, the speed and completeness of HPTA recovery depend on the hypothalamus and pituitary successfully resuming pulsatile GnRH and LH/FSH — and the testes responding with Leydig and Sertoli cell activity. LHCGR and FSHR receptor sensitivity genetics shape the testes' responsiveness to that recovery signal at every step.

HPTA Genetics in the Full Men's Hormone Panel

LH and FSH receptor variants are one of 6 Reproductive Health insights the Precision Peptide Genetic Test analyzes as a connected system — part of the broader framework in the Complete Guide to Genetic Men's Hormone Testing:

SHBG — high SHBG reduces free testosterone, which blunts the androgen-level signal feeding back to the hypothalamus and pituitary. SHBG genetics affect the strength of negative feedback and therefore the intensity of LH/FSH suppression under a given androgen exposure. SHBG Genetics: Why Your Free Testosterone Varies covers this upstream supply dynamic in detail.

CYP19A1 — aromatase converts testosterone to estradiol, and estradiol is in many respects a more potent negative feedback signal to the hypothalamus and pituitary than testosterone itself. High-activity CYP19A1 variants accelerate estrogen-driven HPTA suppression independently of androgen levels. CYP19A1 and Estrogen Conversion in Men covers the aromatase-HPTA connection in full.

AR (CAG repeats) — androgen receptor sensitivity affects how potently androgen-level changes register as feedback signals across the axis. Longer CAG repeats may require larger androgen concentrations to generate equivalent suppression. Androgen Receptor CAG Repeats: Sensitivity Explained covers receptor-level genetics in detail.

SRD5A2 — DHT conversion through 5-alpha reductase generates a potent androgen signal that contributes to the negative feedback picture alongside testosterone and estradiol. SRD5A2 and 5-Alpha Reductase Genetics covers how DHT production genetics fit into the androgen profile.

ESR1 and ESR2 — estrogen receptor variants determine how sensitively the hypothalamus and pituitary respond to the estradiol feedback signal. Higher ESR1 sensitivity at the pituitary level amplifies the suppressive effect of aromatization, making the interplay between CYP19A1 and ESR1 a key determinant of HPTA suppression depth under androgen-pathway conditions.

Together, these 6 insights map the male hormone axis from signal generation at the hypothalamus through receptor responsiveness at the testes — the complete genetic picture of how testosterone is produced, regulated, and preserved.

What Your LH/FSH Receptor Results Can and Cannot Tell You

LH/FSH receptor and FSHB variant analysis reveals your genetic baseline for HPTA axis responsiveness — how sensitively your testes respond to LH and FSH signals, and what your spermatogenic capacity looks like at the receptor level before protocols begin. Results do not measure your current LH, FSH, or sperm parameters; those require blood and semen testing. They do not diagnose any condition. And they do not predict your fertility outcome on any specific protocol.

What they deliver is precise genetic context: the receptor-level terrain your HPTA axis operates on, which informs how providers think about fertility risk, monitor axis function, and build preservation strategies tailored to your individual biology. Genetics as a guide, not a guarantee — and as one of 6 Reproductive Health insights within 14 total pathways and 150+ genetic insights, the HPTA genetics in the Precision Peptide Genetic Test add the dimension most androgen-pathway conversations are still missing entirely.

The Precision Peptide Genetic Test analyzes how your genes influence hormone-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

Ready to understand your HPTA axis genetics and what your LH/FSH receptor variants mean for your hormone profile? Take the Precision Peptide Genetic Test

Frequently Asked Questions About HPTA Axis Genetics

What does HPTA axis genetics measure in the Precision Peptide Genetic Test?

HPTA axis genetics — including LHCGR, FSHR, and FSHB variants — reveal how sensitively the testes respond to LH and FSH signaling. The Precision Peptide Genetic Test analyzes these as part of 6 Reproductive Health insights within 14 total pathways and 150+ genetic insights. Results show receptor-level sensitivity, not current hormone measurements.

Why does HPTA function matter for men on androgen-pathway protocols?

When androgen levels are elevated externally, negative feedback suppresses GnRH, LH, and FSH — reducing testicular testosterone production and sperm output. LHCGR and FSHR variants shape how deeply suppression occurs and how readily the axis recovers. The Precision Peptide Genetic Test maps these variables before protocols begin, giving providers a genetic baseline for fertility risk.

How does CYP19A1 affect HPTA axis suppression?

Estradiol — produced from testosterone via CYP19A1 aromatase — is a potent negative feedback signal to the hypothalamus and pituitary, often more powerful than testosterone itself at that level. High-activity CYP19A1 variants amplify estrogen-driven HPTA suppression. The Precision Peptide Genetic Test analyzes CYP19A1 alongside LH/FSH receptor variants for a complete HPTA axis picture.

This article is part of the PlexusDx Education Hub. Browse all Hormones & Fertility education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.